Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns: Original scientific article. ADMET DMPK [Internet]. 2025 Oct. 14 [cited 2025 Nov. 17];13(5):2956. Available from: https://pub.iapchem.org/ojs/index.php/admet/article/view/2956